# Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

> **NCT06380660** · PHASE1,PHASE2 · RECRUITING · sponsor: **Acerand Therapeutics (Shanghai) Limited** · enrollment: 298 (estimated)

## Conditions studied

- Solid Tumor, Adult
- BRCA1 Mutation
- BRCA2 Mutation
- Ovarian Cancer
- Breast Cancer
- Prostate Cancer

## Interventions

- **DRUG:** ACE-86225106 tablet

## Key facts

- **NCT ID:** NCT06380660
- **Lead sponsor:** Acerand Therapeutics (Shanghai) Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-22
- **Primary completion:** 2028-12-21
- **Final completion:** 2029-03-21
- **Target enrollment:** 298 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06380660

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06380660, "Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06380660. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*